Drug intelligence / Profile preview

INM-088

Development stage: Preclinical
Lead developer: InMed Pharmaceuticals
Modality: Small Molecules
Administration: Ophthalmic

Overview

INM-088 is a cannabinol (CBN)-based drug candidate developed by InMed Pharmaceuticals for the treatment of glaucoma. It is formulated using EyeCRO's MiDROPS® ocular delivery technology, which is designed to enhance the topical administration of cannabinoids to the eye, addressing challenges such as solubility and sustained effect. The therapy aims to reduce intraocular pressure and provide neuroprotection in patients with glaucoma. InMed Pharmaceuticals is advancing INM-088 into IND-enabling toxicology studies.

Targets

CB (Cannabinoid receptors)

Beyond the preview

Go deeper on INM-088.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on INM-088.

Explore the full profile